1. Home
  2. KRNT vs RIGL Comparison

KRNT vs RIGL Comparison

Compare KRNT & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kornit Digital Ltd.

KRNT

Kornit Digital Ltd.

HOLD

Current Price

$15.82

Market Cap

695.1M

Sector

Industrials

ML Signal

HOLD

Logo Rigel Pharmaceuticals Inc.

RIGL

Rigel Pharmaceuticals Inc.

HOLD

Current Price

$34.29

Market Cap

683.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRNT
RIGL
Founded
2002
1996
Country
Israel
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
695.1M
683.2M
IPO Year
2015
2000

Fundamental Metrics

Financial Performance
Metric
KRNT
RIGL
Price
$15.82
$34.29
Analyst Decision
Buy
Strong Buy
Analyst Count
4
5
Target Price
$19.75
$43.20
AVG Volume (30 Days)
405.9K
287.6K
Earning Date
02-11-2026
03-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
2698.26
EPS
N/A
6.20
Revenue
$208,200,000.00
$282,076,000.00
Revenue This Year
$4.28
$66.37
Revenue Next Year
$8.37
N/A
P/E Ratio
N/A
$5.54
Revenue Growth
2.15
79.13
52 Week Low
$11.93
$15.50
52 Week High
$30.03
$52.24

Technical Indicators

Market Signals
Indicator
KRNT
RIGL
Relative Strength Index (RSI) 64.21 43.10
Support Level $14.23 $33.23
Resistance Level $17.96 $34.99
Average True Range (ATR) 0.73 1.46
MACD 0.35 0.15
Stochastic Oscillator 67.74 43.31

Price Performance

Historical Comparison
KRNT
RIGL

About KRNT Kornit Digital Ltd.

Kornit Digital Ltd develops, designs and markets digital printing solutions for the world-wide printed textile industry. The company focuses on its DTG and DTF segments of the printed textile industry. Its solutions include digital printing systems, ink and other consumables, associated software and value-added services that allow for large-scale printing of short runs of complex images and designs directly on finished garments and fabrics. It generates revenue from sales of systems, ink and other consumables and service including software subscriptions The company geographically operates in U.S., EMEA, Asia Pacific and other countries. It derives maximum revenue from U.S.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: